OncoMatch/Clinical Trials/NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Is NCT05900895 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Olaparib and 17b-estradiol for metastatic breast cancer.
Treatment: Olaparib · 17b-estradiol — Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER+)
ER+
Required: HER2 (ERBB2) wild-type (HER2-)
HER2-
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: endocrine-based therapy — advanced/metastatic
Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting
Cannot have received: systemic chemotherapy
Exception: within the last 3 weeks
Any investigational cancer therapy or systemic chemotherapy in the last 3 weeks
Cannot have received: radiation therapy
Exception: within the last 2 weeks
Any radiation therapy in the last 2 weeks
Lab requirements
Kidney function
creatinine clearance > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Cancer Center · Lebanon, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05900895 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy, radiation therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages